These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 2885642)

  • 21. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
    Bredenbeek PJ; Molenkamp R; Spaan WJ; Deubel V; Marianneau P; Salvato MS; Moshkoff D; Zapata J; Tikhonov I; Patterson J; Carrion R; Ticer A; Brasky K; Lukashevich IS
    Virology; 2006 Feb; 345(2):299-304. PubMed ID: 16412488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development.
    Jahrling PB; Peters CJ
    Med Microbiol Immunol; 1986; 175(2-3):165-7. PubMed ID: 3724664
    [No Abstract]   [Full Text] [Related]  

  • 23. Vaccine platforms to control Lassa fever.
    Lukashevich IS; Pushko P
    Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
    Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
    Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Lassa fever virus infection with recombinant nucleocapsid protein antigen.
    Lloyd G; Barber GN; Clegg JC; Kelly P
    Lancet; 1989 Nov; 2(8673):1222. PubMed ID: 2572935
    [No Abstract]   [Full Text] [Related]  

  • 26. Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin.
    Jahrling PB
    J Med Virol; 1983; 12(2):93-102. PubMed ID: 6619814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a new vaccine for the prevention of Lassa fever.
    Geisbert TW; Jones S; Fritz EA; Shurtleff AC; Geisbert JB; Liebscher R; Grolla A; Ströher U; Fernando L; Daddario KM; Guttieri MC; Mothé BR; Larsen T; Hensley LE; Jahrling PB; Feldmann H
    PLoS Med; 2005 Jun; 2(6):e183. PubMed ID: 15971954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
    Pushko P; Geisbert J; Parker M; Jahrling P; Smith J
    J Virol; 2001 Dec; 75(23):11677-85. PubMed ID: 11689649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
    Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
    Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.
    Maruyama J; Mateer EJ; Manning JT; Sattler R; Seregin AV; Bukreyeva N; Jones FR; Balint JP; Gabitzsch ES; Huang C; Paessler S
    Vaccine; 2019 Oct; 37(45):6824-6831. PubMed ID: 31561999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene.
    Fisher-Hoch SP; McCormick JB; Auperin D; Brown BG; Castor M; Perez G; Ruo S; Conaty A; Brammer L; Bauer S
    Proc Natl Acad Sci U S A; 1989 Jan; 86(1):317-21. PubMed ID: 2911575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Scholte FEM; Goldsmith CS; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2019 Sep; 220(8):1281-1289. PubMed ID: 31152662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunogenic and protective characteristics of recombinant Lassa virus NP protein].
    Ignat'ev GM
    Vopr Virusol; 2002; 47(2):28-31. PubMed ID: 12046464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of Lassa fever vaccine candidates.
    Salami K; Gouglas D; Schmaljohn C; Saville M; Tornieporth N
    Curr Opin Virol; 2019 Aug; 37():105-111. PubMed ID: 31472333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.
    Leblanc P; Moise L; Luza C; Chantaralawan K; Lezeau L; Yuan J; Field M; Richer D; Boyle C; Martin WD; Fishman JB; Berg EA; Baker D; Zeigler B; Mais DE; Taylor W; Coleman R; Warren HS; Gelfand JA; De Groot AS; Brauns T; Poznansky MC
    Hum Vaccin Immunother; 2014; 10(10):3022-38. PubMed ID: 25483693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies to Lassa and Lassa-like viruses in man and mammals in the Central African Republic.
    Georges AJ; Gonzalez JP; Abdul-Wahid S; Saluzzo JF; Meunier DM; McCormick JB
    Trans R Soc Trop Med Hyg; 1985; 79(1):78-9. PubMed ID: 2986324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Klena JD; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2018 May; 217(12):1957-1966. PubMed ID: 29800368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
    Abreu-Mota T; Hagen KR; Cooper K; Jahrling PB; Tan G; Wirblich C; Johnson RF; Schnell MJ
    Nat Commun; 2018 Oct; 9(1):4223. PubMed ID: 30310067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lassa fever: implications of T-cell immunity for vaccine development.
    ter Meulen J
    J Biotechnol; 1999 Aug; 73(2-3):207-12. PubMed ID: 10486929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques.
    Jiang J; Banglore P; Cashman KA; Schmaljohn CS; Schultheis K; Pugh H; Nguyen J; Humeau LM; Broderick KE; Ramos SJ
    Hum Vaccin Immunother; 2019; 15(9):2066-2074. PubMed ID: 31071008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.